NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.70▼$15.9150-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume5,955 shsAverage Volume6,668 shsMarket Capitalization$22.68 millionAssets Under Management$18.33 millionDividend Yield1.83%Net Expense Ratio0.79% Stock AnalysisStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial Media Get Range Cancer Therapeutics ETF alerts: Email Address About Range Cancer Therapeutics ETFThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. CNCR ETF News HeadlinesMarch 15, 2024 | msn.comLarge-scale study explores genetic link between colorectal cancer and meat intakeMarch 11, 2024 | markets.businessinsider.comMicrobix Unveils Test Controls for Head and Neck CancerMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 3, 2024 | nasdaq.comThe Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKBFebruary 22, 2024 | msn.comFDA approval of cancer treatment provides new weapon against tumorsFebruary 21, 2024 | msn.comA watershed moment for cancer therapies has arrivedFebruary 5, 2024 | nz.finance.yahoo.comETF S.S.-LONCAR CAN.I.ETF (E18B.BE)January 24, 2024 | msn.comWhy Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?May 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 4, 2024 | markets.businessinsider.comTScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent ProgressSee More Headlines Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings79 Fund Statistics Assets Under Management$18.33 million Average Daily Volume$22,491.60 Discount/Premium-0.09% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest13,900 shs Miscellaneous Outstanding Shares1,430,000Beta1.25 Creation Unit50,000 Creation Fee$150.00 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.34%0.58%Total Expense0.79%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%Net Expense0.79%0.60%0.60%0.54%0.58% Range Cancer Therapeutics ETF (CNCR) Holdings & ExposureTop 10 CNCR HoldingsGeron(NASDAQ:GERN)Holding Weight: 2.78%Acrivon Therapeutics(NASDAQ:ACRV)Holding Weight: 2.54%Enliven Therapeutics(NASDAQ:ELVN)Holding Weight: 2.20%Janux Therapeutics(NASDAQ:JANX)Holding Weight: 1.82%Nuvation Bio(NYSE:NUVB)Holding Weight: 1.75%2seventy bio(NASDAQ:TSVT)Holding Weight: 1.67%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.54%Prelude Therapeutics(NASDAQ:PRLD)Holding Weight: 1.50%Lyell Immunopharma(NASDAQ:LYEL)Holding Weight: 1.48%Adicet Bio(NASDAQ:ACET)Holding Weight: 1.45%CNCR Sector ExposureCNCR Industry ExposureFull Holdings Details Similar ETFsHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHJPMorgan Healthcare Leaders ETFNASDAQ:JDOCInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQProShares UltraShort Nasdaq BiotechnologyNASDAQ:BIS CNCR ETF - Frequently Asked Questions Are investors shorting Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF saw a drop in short interest in April. As of April 15th, there was short interest totaling 13,900 shares, a drop of 50.2% from the March 31st total of 27,900 shares. Based on an average daily volume of 36,900 shares, the days-to-cover ratio is currently 0.4 days. View Range Cancer Therapeutics ETF's Short Interest. What does CNCR invest in? Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $18.33 million assets under management. What stocks does Range Cancer Therapeutics ETF hold? CNCR invests in 79 holdings. Some of the stocks in their portfolio include Geron (GERN), Acrivon Therapeutics (ACRV), Enliven Therapeutics (ELVN), Janux Therapeutics (JANX), Nuvation Bio (NUVB), 2seventy bio (TSVT), Revolution Medicines (RVMD), Prelude Therapeutics (PRLD), Lyell Immunopharma (LYEL) and Adicet Bio (ACET). What is the management fee for Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%. What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX). This page (NASDAQ:CNCR) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.